<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180104038218N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-18</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the efficacy of oral sweet taste in making dental treatment of 4-6 years old children more pleasant</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the efficacy of oral sweet taste in making dental treatment of 4-6 years old children more pleasant</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65841</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization using an sealed envelope with an equal number of intervention (sweet taste) and control (water) samples is placed in a package and provided to the ward nurse, each time the nurse (Who has no role in the continuation of the study) pulls one of the envelopes and it is determined that the patient receives intervention or control, Blinding description: Outcome assessment is performed by a person other than the researcher and clinical caregiver and because he / she is present at the patient's bedside after the intervention, he / she is blind to the received intervention.
The grouping results of each sample are delivered to the statistical analyzer in the form of numbers, so the analyzer is also blind. According to the sweet taste in the mouth of the intervention group, the participants are not blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>treatment in pediatric dentistry.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: In the first session, all children are subjected to brushing treatment and fluoride therapy with the tell show do technique in order to evaluate cooperation and shape their behavior. In the next session, the child is randomly assigned to one of the first and second groups and receives dental treatment. In both groups, 2% lidocaine and 1/100,000 epinephrine were used to anesthetize the region with the supra periosteal technique, and the injection syringe was not placed in the child's viewing angle in both groups. In the intervention group, pulp therapy of the maxillary molar is performed in the condition where sweet taste prevails in the mouth; Therefore, after anesthesia injection, the child kept a 25% sweet solution (25 g of sucrose (Merck, Germany) - 75 cc of distilled water) in the mouth for one minute, and then, honey is applied with a swab in the buccal vestibule of the mandible, in the opposite quadrant. If the honey is washed, this process is repeated every 2 minutes. Intervention 2: Control group: Control group: In the first session, all children are subjected to brushing and fluoride therapy with the tell show do technique in order to evaluate cooperation and shape their behavior. In the next session, the child is randomly assigned to one of the first and second groups and receives dental treatment. In both groups, 2% lidocaine and 1/100,000 epinephrine were used to anesthetize the region with the supra periosteal technique, and the injection syringe was not placed in the child's viewing angle in both groups. In the control group, the maxillary molar receives pulp therapy under normal conditions. In control group , after the anesthetic injection, the child holds normal water in his mouth for one minute and then spits it out. During the treatment, a dry swab is drawn in the buccal vestibule on the opposite side of the treatment and this is repeated every two minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Razieh Jabbarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar Boulvard</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3471976160</zip>
        <telephone>+98 28 3335 3062</telephone>
        <email>r.jabbarian@qums.ac.ir</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Razieh Jabbarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar Boulvard</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3471976160</zip>
        <telephone>+98 28 3335 3062</telephone>
        <email>r.jabbarian@qums.ac.ir</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>4-6 year old children in need of maxillary first molar pulp treatment
Physical health in terms of systemic and development
positive behavior according to Frankel's classification (cooperative and without resistance to treatment)
They should not eat or drink anything at least one hour before the treatment
Without previous dental experience</inclusion_criteria>
      <agemin>4 years</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy or contraindication regarding consumption of sweet substances
Spontaneous/nocturnal pain or abscess in the target tooth
Presence of pain, inflammation and any other problem in the treatment area
If complete anesthesia was not achieved for the treatment, the patient will be excluded from the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute pain, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: In the first session, all children are subjected to brushing treatment and fluoride therapy with the tell show do technique in order to evaluate cooperation and shape their behavior. In the next session, the child is randomly assigned to one of the first and second groups and receives dental treatment. In both groups, 2% lidocaine and 1/100,000 epinephrine were used to anesthetize the region with the supra periosteal technique, and the injection syringe was not placed in the child's viewing angle in both groups. In the intervention group, pulp therapy of the maxillary molar is performed in the condition where sweet taste prevails in the mouth; Therefore, after anesthesia injection, the child kept a 25% sweet solution (25 g of sucrose (Merck, Germany) - 75 cc of distilled water) in the mouth for one minute, and then, honey is applied with a swab in the buccal vestibule of the mandible, in the opposite quadrant. If the honey is washed, this process is repeated every 2 minutes</i_keyword>
      <i_keyword>Control group: Control group: In the first session, all children are subjected to brushing and fluoride therapy with the tell show do technique in order to evaluate cooperation and shape their behavior. In the next session, the child is randomly assigned to one of the first and second groups and receives dental treatment. In both groups, 2% lidocaine and 1/100,000 epinephrine were used to anesthetize the region with the supra periosteal technique, and the injection syringe was not placed in the child's viewing angle in both groups. In the control group, the maxillary molar receives pulp therapy under normal conditions. In control group , after the anesthetic injection, the child holds normal water in his mouth for one minute and then spits it out. During the treatment, a dry swab is drawn in the buccal vestibule on the opposite side of the treatment and this is repeated every two minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The objective level of pleasant treatment. Timepoint: during treatment. Method of measurement: FLACC( Face,leg,activity,crying,consolability).</prim_outcome>
      <prim_outcome>The objective level of pleasant treatment. Timepoint: after treatment. Method of measurement: Wong baker.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: before, during and after treatment. Method of measurement: pulse oximeter.</prim_outcome>
      <prim_outcome>Oxygen saturation. Timepoint: before, during and after treatment. Method of measurement: pulse oximeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-03</approval_date>
        <contact_name>Ethics Committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>Bahonar Boulvard Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
